B Cells Directly Tolerize CD8⁺ T Cells

By Sally R. M. Bennett,*‡ Francis R. Carbone,§ Tracey Toy,§ Jacques F. A. P. Miller,* and William R. Heath*

From the *Immunology Division, The Walter and Eliza Hall Institute of Medical Research, The Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia; ‡The Cooperative Research Centre for Vaccine Technology at the Queensland Institute of Medical Research, The Royal Brisbane Hospital, Herston, Queensland 4029, Australia; and the §Department of Pathology and Immunology, Monash Medical School, Prahran, Victoria 3181, Australia

Summary

This report investigates the response of CD8⁺ T cells to antigens presented by B cells. When C57BL/6 mice were injected with syngeneic B cells coated with the Kᵇ-restricted ovalbumin (OVA) determinant OVA 257–264, OVA-specific cytotoxic T lymphocyte (CTL) tolerance was observed. To investigate the mechanism of tolerance induction, in vitro–activated CD8⁺ T cells from the Kᵇ-restricted, OVA-specific T cell receptor transgenic line OT-I (OT-I cells) were cultured for 15 h with antigen-bearing B cells, and their survival was determined. Antigen recognition led to the killing of the B cells and, surprisingly, to the death of a large proportion of the OT-I CTLs. T cell death involved Fas (CD95), since OT-I cells deficient in CD95 molecules showed preferential survival after recognition of antigen on B cells. To investigate the tolerance mechanism in vivo, naive OT-I T cells were adoptively transferred into normal mice, and these mice were co-injected with antigen-bearing B cells. In this case, OT-I cells proliferated transiently and were then lost from the secondary lymphoid compartment. These data provide the first demonstration that B cells can directly tolerize CD8⁺ T cells, and suggest that this occurs via CD95-mediated, activation-induced deletion.

Key words: CD8⁺ T lymphocytes • cytotoxic T lymphocytes • antigen presentation • B cells • ovalbumin

B cells express relatively high levels of class I MHC molecules and therefore potentially play a role as APCs for CD8⁺ T cells. In vitro evidence suggests that B cells can stimulate IL-2 production and CTL activity by either primed CD8⁺ T cell clones or hybridomas (1–3). However, studies in B cell-deficient mice suggest that B cells are not required as APCs during the inductive phase of naive CD8⁺ T cell responses (4). In fact, it has been reported that B cells fail to induce naive CD8⁺ T cells to generate primary CTL activity in vitro (5) and can induce secondary in vitro unresponsiveness in CD8⁺ T cell clones (6). In adult mice, B cells have been shown to induce in vivo CTL tolerance to the minor antigen H-Y (7), but whether this was due to direct tolerance of the CD8⁺ T cell compartment was not addressed. CTL responses to H-Y are known to be CD4⁺ T cell dependent (8, 9), and there is a great deal of evidence that B cell presentation of antigen to mature CD4⁺ T cells is tolerogenic (10–16). Thus, it was unclear whether H-Y-specific CTL tolerance was due to the direct tolerance of CD8⁺ T cells or occurred because H-Y-specific helper T cells were tolerized. In this latter case, the CTLs themselves might have been completely unaffected by antigen-bearing B cells, but failed to be primed in the absence of CD4⁺ T cell help. In this report, we demonstrate that CD8⁺ T cells can be directly tolerized after encounter with antigen on B cells. The basis of this tolerance is examined.

Materials and Methods

Mice. Mice were bred and maintained at the Walter and Eliza Hall Institute for Medical Research. OT-I mice have been described previously (17), and were maintained on the recombinase-activating gene (RAG)⁻¹-deficient C57BL/6 (B6) background. Some experiments used OT-I mice expressing the lpr mutation (OT-I.lpr) or back-crossed to bm1; both of these strains were RAG-1 sufficient. For all experiments, mice between 8 and 16 wk of age were used.

B Cell Purification. B cells were purified as described previously (16). In brief, spleen cells were depleted of red blood cells,
and passed over a 30–35-ml Sephadex G-10 column (Amersham Pharmacia Biotech, Uppsala, Sweden) to remove adherent cells. T cells were then removed by treatment with a mixture of anti-Thy1.2 (J1), anti-CD8 (B3/18), and anti-CD4 (R1L72) antibody supernatants at 4°C for 30 min, followed by two successive treatments with rabbit C (C-Six Diagnostics Inc., Mepquon, WA) at 37°C for 20 min. After passage over a second Sephadex G-10 column, the cells were analyzed by flow cytometry using anti-B220–FITC and found to be >95% B220+. To separate small, resting B cells, the B cell suspension was centrifuged at 3,000 rpm for 30 min over a discontinuous Percoll (Amersham Pharmacia Biotech) density gradient containing ρ = 1.05–1.09 layers as described previously (16). Cells from the ρ = 1.07–1.09 interface were used as resting B cells. B cells were coated at 5 × 10^6/ml with 0, 0.1, 1.0, or 10 μg/ml OVA257–264 peptide in Hepes Eagle’s M edium (HEM) containing 2.5% FCS for 60 min at 37°C and washed three times before counting. M ice were immunized intravenously with 10–15 × 10^6 B cells in HEM.

Dendritic Cell Generation. Bone marrow–derived dendritic cells were prepared as described previously (18) with the following modifications. In brief, bone marrow cells from B6 mice were cultured in 94-mm tissue culture dishes (Greiner Labortechnik, Frickenhausen, Germany) at a density of 5 × 10^5/ml in complete DMEM with 10% FCS as well as 5% supernatant of X63-Ag8.653 (HEM) containing 2.5% FCS for 60 min at 37°C and washed overnight in fresh GM-CSF-containing media. Nonadherent dendritic cells were harvested the next day and used for immunization.

CTL Challenge. 1 wk after immunization with B cells, B6 mice were challenged with an intravenous injection of 20–25 × 10^6 irradiated spleen cells loaded intracytoplasmically with OVA by osmotic shock, or with a subcutaneous injection of 10–20 μg OVA257–264 in CFA as described previously (19).

In Vitro Generation of OVA-specific CTLs. CTLs were generated as described previously (19). LU/spleen were calculated as the total number of CTL effectors present after the 6 d of in vitro stimulation, divided by the number of effectors required to give 95% B220+ cells. B cells in HEM.

B Cells Directly Tolerize CD8+ T Cells

**Results**

B cell Presentation of Antigen Causes Direct Tolerance of CD8+ T Cells. Presentation of antigen by B cells has been shown to cause CTL tolerance for the male-specific anti-H-Y response (7). However, this response is dependent on CD4+ T cell help (8, 9), raising the possibility that CTL tolerance occurred indirectly by the induction of CD4+ T cell tolerance. To investigate whether antigen-bearing B cells can induce tolerance by directly affecting the CD8+ T cell population, B cells coated with the Kb-restricted OVA peptide OVA257–264 were tested for their ability to tolerate OVA-specific CTL responses generated by intravenous injection of irradiated spleen cells loaded intracytoplasmically with OVA protein (OVA-loaded spleen cells [21]). Injection of B6 mice with 10^6 OVA257–264-coated B cells reduced the subsequent OVA-specific CTL response upon challenge with OVA-loaded spleen cells (Fig. 1a). On average, the ability to generate OVA-specific CTLs was diminished 10-fold, but many mice showed >100-fold weaker responses (Fig. 1a). Tolerance induction by B cells was long-lasting, as thymectomized mice injected with OVA257–264-coated B cells were unable to generate OVA-specific CTLs 12 wk after immunization (data not shown).

The level of antigen expression also affected tolerance induction, which was slightly more efficient when B cells were coated with a higher concentration (10 vs. 1 μg/ml) of peptide (Fig. 1b). Although CD4+ T cell tolerance induction by B cells has been shown to be more...
We have found that the priming protocol used to measure CD8\(^+\) T cell tolerance induction by B cells, i.e., OVA\(^{257-264}\)-loaded spleen cell challenge, is CD4\(^+\) T cell dependent (19). Therefore, it was possible (though unlikely given that tolerization only involved the class I–restricted determinant (19)) that CTL tolerance in this model may have also occurred indirectly through the induction of CD4\(^+\) T cell tolerance. To determine whether tolerance resulted from a direct effect on CD8\(^+\) T cells, we examined cell tolerance induction under conditions where CTL generation was not CD4\(^+\) T cell dependent, i.e., by priming subcutaneously with OVA\(^{257-264}\) in CFA (19). OVA\(^{257-264}\)-coated B cell–primed mice challenged subcutaneously with OVA\(^{257-264}\) in CFA also failed to generate OVA–specific CTLs (Fig. 1 b), confirming that the CD8\(^+\) T cells were directly tolerated.

A divalent CD8\(^+\) T cells die after recognizing an antigen on B cells in vitro. To investigate the mechanism of CTL tolerance induction by antigen-bearing B cells, we examined the in vitro response of activated CD8\(^+\) T cells to antigen-bearing B cells. For these experiments, in vitro–activated CD8\(^+\) T cells from the OVA–specific TCR transgenic line OT-I were used. These mice are of a B6 genotype. OT-I cells plus syngeneic B6 B cells (unpulsed or pulsed with OVA\(^{257-264}\)) were cultured together for 15 h and then analyzed by flow cytometry to determine the survival of each cell population relative to an internal control population of bm1 B cells. These latter cells bear the Kb\(^{bm1}\) MHC molecule and therefore cannot present OVA\(^{257-264}\) to OT-I cells (20). The survival of the OT-I cells (B220\(^-\), Kb\(^{+}\)) and B6 B cells (B220\(^+\), Kb\(^{+}\)) was then examined relative to the bm1 control B cells (B220\(^+\), Kb\(^-\)) (Fig. 2, a and b). As expected, the activated OT-I cells killed a large proportion of B6 B cells, as seen by the reduction in B6 B cells relative to bm1 B cells in the presence of antigen. Surprisingly, there was also a dramatic loss of OT-I cells relative to the bm1 B cell control population. Six separate experiments revealed a consistent loss of the CD8\(^+\) CTLs during their 15-h culture with antigen-bearing B6 B cells. This result was the same whether the bm1 B cells were cocultured as described above, or whether they were simply added at the end of the culture period, just before flow cytometric analysis. In an example of the latter experiment, there were 2.1 \(\times\) 10\(^5\) OT-I cells and 1.7 \(\times\) 10\(^5\) B6 B cells present after 15 h of

**Figure 1.** OVA\(^{257-264}\)-coated B cells induce OVA–specific CTL tolerance in B6 mice. B6 mice were injected intravenously with 10\(^5\) OVA\(^{257-264}\)-coated B6 cells, unpulsed B6 B cells, or medium alone, and rechallenged 7 d later with (a and c) 25 \(\times\) 10\(^4\) OVA–loaded spleen cells injected intravenously or (b) 10 \(\mu\)g OVA\(^{257-264}\) in CFA injected subcutaneously. After an additional 7 d, their spleens were removed and stimulated in vitro for 6 d before a 4-h chromium release assay was performed. (a and b) Percent specific lysis of 51Cr-labeled OVA\(^{257-264}\)-coated EL4 (filled symbols) and EL4 (open symbols) in mice injected with B cells coated with OVA\(^{257-264}\) at 10 \(\mu\)g/ml (squares) or with medium alone (circles). (c) The number of OVA–specific LU/spleen for individual mice (filled triangles treated as in a) and calculated as described in Materials and Methods. OVA\(^{257-264}\), OVA\(^{257-264}\) coated. 0 per circle, average LU/spleen for each group.

**Figure 2.** Activated OT-I cells kill peptide-coated B cells, but are themselves killed by a CD95–dependent mechanism during this recognition process. 5 \(\times\) 10\(^5\) previously stimulated (a and b) OT-I cells or (c and d) OT-I.lpr cells were cultured for 15 h with 5 \(\times\) 10\(^5\) B6 plus bm1 B cells coated without (a and c) or with (b and d) 0.1 \(\mu\)g/ml OVA\(^{257-264}\) peptide. The wells were then analyzed by flow cytometry using anti-B220–FITC and anti-Kb\(^{+}\) (5-F-1)–biotin followed by Streptavidin–PE.
culture in the absence of peptide. When the B6 B cells were first coated with peptide, only \(0.31 \times 10^5\) OT-I cells and \(0.83 \times 10^5\) B6 B cells remained. This represents an 85% loss of OT-I cells and a 51% loss of B6 B cells.

The antigen-specific loss of OT-I cells was not due to fratricide as a result of re-presentation of OVA peptide by CTLs to each other, since OT-I cells bearing the non-presenting K\(^{bm}\) molecule, instead of K\(^{b}\), were also killed (data not shown). To investigate whether Fas (CD95)-mediated signaling (for a review, see reference 22) was involved in the death of activated CD8\(^{+}\) T cells, the OT-I mice were crossed to lpr mice, which express a genetic defect in CD95 (23). When activated OT-I.lpr cells were cultured for 15 h with antigen-bearing B cells, survival was greatly improved (Fig. 2, c and d). This suggested that activated cells were killed by a CD95-dependent mechanism. Unlike activated OT-I cells, naive OT-I cells did not kill antigen-bearing B cells and were not killed during this 15-h culture period (data not shown).

Discussion

Most studies examining tolerance induction by B cells have focussed on the response of CD4\(^{+}\) T cells (10–16). This report represents the first demonstration that naive CD8\(^{+}\) T cells can be directly tolerized by recognition of antigen on B cells. One other study has addressed the role of B cells as tolerogenic APCs in vivo for CD8\(^{+}\) T cell responses by showing that injection of male B cells into female mice resulted in H-Y–specific CTL tolerance (7). However, generation of H-Y–specific CTLs has been reported to require CD4\(^{+}\) T cell help (8, 9). Thus, failure to induce H-Y–specific CTLs might have simply reflected tolerant CD4\(^{+}\) T helper cells. We showed that OVA-spe-
cific CTLs were directly tolerized by OVA 257–264-Coated B cells, since mice primed with OVA 257–264 peptide-coated B cells responded weakly to both OVA-loaded spleen cells (Fig. 1, a and c) and OVA peptide in CFA (Fig. 1 b). This latter response is CD4+ T cell independent, indicating that CTLs exposed to B cells bearing class I–restricted determinants are directly tolerized.

Since CTL tolerance has been reported to be the default response when CD4 help is unavailable (24, 25), it is possible that B cells induced CTL tolerance simply because they failed to provide determinants for stimulation of CD4+ T cell help. Even if class II–restricted determinants had been available, naïve CD4+ T cells are reported to be tolerized by recognition of antigen on B cells, which should also lead to a lack of help and, consequently, CTL tolerance. It remains to be addressed whether provision of primed CD4+ T cell help, which cannot be tolerized by B cells, will allow B cells to stimulate naïve CTL responses.

Our in vitro studies showed that peptide-coated B cells could be lysed by activated OT-I cells, confirming that CD8+ T cells could recognize antigen on B cells (Fig. 2). More importantly, however, these experiments revealed that activated, but not naïve, OT-I cells died shortly after interacting with antigen-bearing B cells. The loss of activated OT-I cells after recognition of antigen on B cells suggested that the pathway to B cell-mediated tolerance induction may require the interaction of activated CD8+ T cells with B cells. Protection of activated OT-I.lpr CD8+ T cells from death implied that CD95-mediated signaling played an important role in this death pathway.

A great deal of evidence suggests that CD95-mediated signaling is the predominant mediator of CD4+ T cell death in vitro via a mechanism termed activation-induced cell death (AICD [26–30]). This is mediated through the interaction of CD95 with its ligand (CD95L [31, 32]), expressed on the same (26, 27) or neighboring (33, 34) antigen-activated T cells, and occurs within 24 h for previously activated cells (35). Although there is some evidence that CD95 is involved in the death of activated CD8+ T cells (33, 36, 37), TNFR/TNF-mediated apoptosis has also been suggested to be important (35, 38, 39). This latter mechanism takes 40–48 h to induce apoptosis of activated T cells (35). Our observation that up to 85% of activated CD8+ T cells were killed within 15 h argues against a role for TNFR signaling for B cell–induced deletion of CD8+ T cells. The fact that activated CD8+ T cells expressing the mutant CD95 gene were largely protected from deletion suggests that CD95/CD95L interactions are more important in this case.

It was at first surprising that naïve OT-I cells, in contrast to activated OT-I cells, were not killed when cultured for 15 h in vitro with antigen-bearing B cells. Interestingly, cultures containing naïve OT-I cells showed extensive proliferation on day 2 (data not shown). This is consistent with the idea that to be deleted, OT-I cells must first be activated and, as a consequence, may proliferate before being killed. However, the combined effects of proliferation, nutrient utilization, and activation-induced cell death in vitro made it very difficult to analyze the response of naive OT-I cells under these conditions; therefore, we concentrated our efforts on examining the response of naïve OT-I cells in vivo.

Deletional tolerance after antigen-specific activation in vivo has been reported for both CD4+ and CD8+ T cells responding to a variety of antigens. These include conventional peptide or protein antigens (40–42), superantigens (43–47), minor antigens (48), viral antigens (49, 50), and tissue-specific antigens (51–53). These studies were characterized by an early, transient period of antigen-specific T cell proliferation followed by rapid deletion of most responding T cells. OT-I cells displayed similar response kinetics upon exposure to peptide-coated B cells in vivo (Fig. 3). At day 3, there was marked proliferation of OT-I cells, but by day 7 the number of OT-I cells had declined to below prestimulation levels, where it remained. Altogether, our data suggest that B cells tolerate CD8+ T cells via activation of naive cells followed by CD95-mediated deletion of their activated progeny.

Interestingly, not all OT-I cells were deleted in response to OVA-bearing B cells. Unlike other models where those T cells that remain become hyporesponsive to further antigen challenge (40, 41, 44, 48, 52), the OT-I cells that were not deleted showed full CTL function (Fig. 4). Given that deletion is reported to be antigen dose dependent (42, 43), these cells may represent OT-I cells that were inadequately stimulated by the tolerogenic B cells. Perhaps all of the B cells were killed before all activated CD8+ T cells could reencounter antigen for induction of CD95-mediated death. We attempted to address this issue by introducing a second dose of OVA-coated B cells 5 d after the first immunization, but this only slightly enhanced OT-I deletion at day 14. However, in TCR transgenic models, changes to the extent and nature of tolerance induction may require very large variations in antigen dose due to the relatively high number of responsive T cells (52, 54).

It is important to note that we have not addressed whether B cells are unique in their ability to induce deletion of CD8+ T cells. It may be that any cell type lacking the appropriate accessory signals will cause such deletion. The aim of this report was to specifically examine the effect of antigen presentation by B cells to CD8+ T cells. To this end, we have shown that B cells are directly tolerogenic for CD8+ T cells. This tolerance appears to be preceded by activation and proliferation of antigen-specific CD8+ T cells. Once activated, CD8+ T cells appear to be susceptible to CD95-mediated killing by reencounter with antigen on B cells, at least in vitro. Taken together, our data suggest that B cell presentation of antigen to CD8+ T cells leads to activation followed by deletion of the antigen-specific population.
We thank Freda Karamalis, Paula Nathan, Jenny Falso, and Tatiana Banjanin for technical assistance.

This work was supported by the Cooperative Research Centre for Vaccine Technology, the National Institutes of Health (grant AI-29385), and grants from the National Health and Medical Research Council and the Australian Research Council.

Address correspondence to William R. Heath, Immunology Division, The Walter and Eliza Hall Institute, Post Office Box Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia. Phone: 61-3-9345-2482; Fax: 61-3-9347-0852; E-mail: heath@wehi.edu.au

Received for publication 26 December 1997 and in revised form 15 September 1998.

References

29. Owen-Schaub, L.B., S. Yonehara, W.L. Crump III, and E.A. Grimm. 1992. DNA fragmentation and cell death is selec-
tively triggered in activated human lymphocytes by Fas anti-
30. Alderson, M.R., T.W. Tough, T. Davis-Smith, S. Braddy, B. Fal-
k, K.A. Schooley, R.G. Goodwin, C.A. Smith, F. Rams-
dell, and D.H. Lynch. 1995. Fas ligand mediates activation-
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169–1178.
pathway of apoptotic cell death is defective in the mature per-
34. Vignaux, F., and P. Golstein. 1994. Fas-based lymphocyte-
mediated cytotoxicity against syngeneic activated lympho-
ture T cells of autoimmune lpr/lpr mice have a defect in anti-
4413.
Carbone. 1998. The peripheral deletion of autoreactive CD8
38. Alexander-Miller, M.A., G.R. Leggatt, A. Sarin, and J.A.
Berzofsky. 1996. Role of antigen, CD8, and cytotoxic T
lymphocyte (CTL) avidity in high dose antigen induction of
Pfeffer, T.W. Mak, and P.S. Ohashi. 1996. Tumor necrosis
factor receptor p55 mediates deletion of peripheral cytotoxic T
Zinkernagel, and H. Pircher. 1993. T cell immunity after a
viral infection versus T cell tolerance induced by soluble viral
Visualization of peptide-specific T cell immunity and
42. Liblau, R.S., R. Tisch, K. Shokat, X. Yang, N. Dumont,
C.C. Goodnow, and H.O. McDevitt. 1996. Intravenous injec-
tion of soluble antigen induces thymic and peripheral T-cells
43. Webb, S., C. Morris, and J. Sprent. 1990. Extrathymic toler-
ance of mature T cells: clonal elimination as a consequence of
44. Kawabe, Y., and A. Ochi. 1991. Programmed cell death and
extrathymic reduction of Vβ8+ CD4+ T cells in mice tolerant
to Staphylococcus aureus enterotoxin B. Nature. 349:245–
248.
expansion precedes anergy and death of Vβ8+ peripheral T
46. McCormack, J.E., J.E. Callahan, J. Kappler, and P.C. Marrack.
1993. Profound deletion of mature T cells in vivo
47. Gonzalez, J.A., I. Moreno de Alboran, J.E. Ales-Martinez, C.
Martinez, and G. Kroemer. 1992. Expansion and clonal dele-
tion of peripheral T cells induced by bacterial superantigen is
22:1007–1011.
49. Moskophidis, D., F. Lechner, H. Pircher, and R.M. zincern-
agel. 1993. Virus persistence in acutely infected immuno-
competent mice by exhaustion of antiviral cytotoxic effector
50. Zinkernagel, R.M., D. Moskophidis, T. Kundig, S. Oehen,
H. Pircher, and H. Hengartner. 1993. Effector T-cell induc-
tion and T-cell memory versus peripheral deletion of T cells.
Heath. 1997. Class I-restricted cross-presentation of exogenous self antigens leads to deletion of autoreactive CD8
+ T cells in mice toler-
ated by chronic exposure to exogenous superantigen. Eur.
1993. Profound deletion of T cells upon chronic exposure to